Senseonics (NYSE:SENS) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a research report report published on Friday morning. The firm issued a sell rating on the stock.

Separately, HC Wainwright reiterated a buy rating and set a $2.00 price target on shares of Senseonics in a research note on Wednesday, August 14th.

Senseonics Price Performance

SENS stock opened at $0.41 on Friday. Senseonics has a 12 month low of $0.32 and a 12 month high of $0.75. The company has a debt-to-equity ratio of 59.17, a current ratio of 3.11 and a quick ratio of 2.89. The company has a market cap of $217.92 million, a price-to-earnings ratio of -2.91 and a beta of 0.79. The company has a fifty day moving average price of $0.41 and a 200 day moving average price of $0.45.

Senseonics (NYSE:SENS) last announced its earnings results on Thursday, August 8th. The company reported ($0.03) EPS for the quarter, meeting analysts’ consensus estimates of ($0.03). Senseonics had a negative net margin of 335.15% and a negative return on equity of 299.69%. The business had revenue of $4.87 million during the quarter, compared to analysts’ expectations of $4.86 million. Sell-side analysts expect that Senseonics will post -0.13 earnings per share for the current year.

Institutional Investors Weigh In On Senseonics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. RPO LLC purchased a new position in shares of Senseonics in the fourth quarter valued at $37,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Senseonics in the first quarter valued at about $91,000. Virtu Financial LLC acquired a new stake in shares of Senseonics in the first quarter valued at approximately $162,000. Cubist Systematic Strategies LLC increased its stake in shares of Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in Senseonics by 16.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after buying an additional 51,000 shares in the last quarter. 12.36% of the stock is currently owned by institutional investors and hedge funds.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.